Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | CDA | P32320 | 8/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026520 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL799668 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL20345667 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL10324251 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL14768699 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL15617563 | 0.89 | PDE4D (0.35) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL12758154 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL14073159 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL15334647 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL14262807 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | SIGNAL PHARM LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9220696-B2 | Pharmaceutical combinations for treatment of specific cancers | ARDEA BIOSCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150057357-A1 | BIS (THIOHYDRAZIDE AMIDE) COMPOUNDS FOR TREATING CANCERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-02-26 | — | — | US | disclosed |
| US-20140080783-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130142805-A1 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| US-8350023-B2 | Crystalline polymorphs of gemcitabine base | ScnioPharm Taiwan, Ltd. (TW) | 2013-01-08 | — | — | US | disclosed |
| US-20120135001-A1 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DASATINIB FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-31 | — | — | US | disclosed |
| US-20120071435-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20090326214-A1 | Crystalline Polymorphs of Gemcitabine Base | SCINOPHARM TAIWAN LTD. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135001-A1 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DASATINIB FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PTPRJ, PTPRCAP, PTPRC | PDE4D 1275/4885PDE3A 2058/4885SLC29A1 1306/4885 |
| US-20090326214-A1 | Crystalline Polymorphs of Gemcitabine Base | TYMP, BLM, TOP2B | PDE4D 1953/4885PDE3A 2374/4885SLC29A1 37/4885 |
| US-20120071435-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS | TP53, KRAS, PAICS | PDE4D 1751/4885PDE3A 1648/4885SLC29A1 3404/4885 |
| US-20150057357-A1 | BIS (THIOHYDRAZIDE AMIDE) COMPOUNDS FOR TREATING CANCERS | OGG1, UNG, TP53 | PDE4D 4164/4885PDE3A 3997/4885SLC29A1 1534/4885 |
| US-20130142805-A1 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES | MALT1, PTPRJ, PTPRCAP | PDE4D 1047/4885PDE3A 2569/4885SLC29A1 1012/4885 |
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | MTOR, ULK2, TTK | PDE4D 3089/4885PDE3A 3057/4885SLC29A1 3538/4885 |
| US-20140080783-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS | TP53, KRAS, PAICS | PDE4D 1185/4885PDE3A 1427/4885SLC29A1 3290/4885 |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | MTOR, ULK2, TTK | PDE4D 3089/4885PDE3A 3057/4885SLC29A1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.